| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adherence to allopurinol in patients with gout: further insights generate further questions
|
Robinson, Philip C
|
|
|
|
5 |
p. e249-e250
|
artikel
|
| 2 |
Allopurinol adherence and its predictors in gout: a national cohort study in US veterans
|
Singh, Jasvinder A
|
|
|
|
5 |
p. e281-e291
|
artikel
|
| 3 |
A molecular signature as a guidance for glucocorticoid: are we there yet?
|
Fu, Yakai
|
|
|
|
5 |
p. e315-e317
|
artikel
|
| 4 |
Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis
|
van Wesemael, T J
|
|
|
|
5 |
p. e316-e317
|
artikel
|
| 5 |
Arthritis after SARS-CoV-2 infection
|
Baimukhamedov, Chokan
|
|
|
|
5 |
p. e324-e325
|
artikel
|
| 6 |
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study
|
Pfeifer, Jochen
|
|
|
|
5 |
p. e329-e337
|
artikel
|
| 7 |
Bilateral linear scleroderma with transition into progressive facial hemiatrophy
|
Kreuter, Alexander
|
|
|
|
5 |
p. e374
|
artikel
|
| 8 |
Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?
|
Baker, Kenneth F
|
|
|
|
5 |
p. e371-e382
|
artikel
|
| 9 |
Caution and clarity required in the use of chloroquine for COVID-19
|
Wong, Yin Kwan
|
|
|
|
5 |
p. e255
|
artikel
|
| 10 |
Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine
|
Nijs, Jo
|
|
|
|
5 |
p. e383-e392
|
artikel
|
| 11 |
Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial
|
Døssing, Anna
|
|
|
|
5 |
p. e254-e262
|
artikel
|
| 12 |
Correction to Lancet Rheumatol 2023; 5: e274–83
|
|
|
|
|
5 |
p. e251
|
artikel
|
| 13 |
COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics
|
Lloyd-Jones, Graham
|
|
|
|
5 |
p. e325-e326
|
artikel
|
| 14 |
COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics – Author's reply
|
McGonagle, Dennis
|
|
|
|
5 |
p. e326
|
artikel
|
| 15 |
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
|
Boekel, Laura
|
|
|
|
5 |
p. e310-e313
|
artikel
|
| 16 |
Dapansutrile: a new hope?
|
Toprover, Michael
|
|
|
|
5 |
p. e247-e249
|
artikel
|
| 17 |
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
|
Klück, Viola
|
|
|
|
5 |
p. e270-e280
|
artikel
|
| 18 |
Digital ulcers: should debridement be a standard of care in systemic sclerosis?
|
Hughes, Michael
|
|
|
|
5 |
p. e302-e307
|
artikel
|
| 19 |
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study
|
Rodziewicz, Mia
|
|
|
|
5 |
p. e284-e292
|
artikel
|
| 20 |
Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?
|
Taylor, Peter C
|
|
|
|
5 |
p. e241-e243
|
artikel
|
| 21 |
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study
|
Conaghan, Philip G
|
|
|
|
5 |
p. e263-e273
|
artikel
|
| 22 |
Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial
|
Riches, Philip L
|
|
|
|
5 |
p. e320-e328
|
artikel
|
| 23 |
Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology
|
Owens, Brian
|
|
|
|
5 |
p. e257
|
artikel
|
| 24 |
First manifestation of adult-onset Still's disease after COVID-19
|
Bamidis, Anna D
|
|
|
|
5 |
p. e319-e321
|
artikel
|
| 25 |
Getting serious about sex and gender
|
The Lancet Rheumatology,
|
|
|
|
5 |
p. e313
|
artikel
|
| 26 |
Global rheumatology in the time of COVID-19
|
Lewandowski, Laura B
|
|
|
|
5 |
p. e254-e255
|
artikel
|
| 27 |
Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study
|
Northcott, Melissa
|
|
|
|
5 |
p. e357-e370
|
artikel
|
| 28 |
Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
|
Connolly, Caoilfhionn M
|
|
|
|
5 |
p. e307-e308
|
artikel
|
| 29 |
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
|
Wieske, Luuk
|
|
|
|
5 |
p. e338-e350
|
artikel
|
| 30 |
IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2
|
Bassiri, Hamid
|
|
|
|
5 |
p. e305-e307
|
artikel
|
| 31 |
Is it Autumn for colchicine and osteoarthritis?
|
Watt, Fiona E
|
|
|
|
5 |
p. e240-e241
|
artikel
|
| 32 |
Latika Gupta: a thinker and a doer for myositis research
|
Morgan, Jules
|
|
|
|
5 |
p. e319
|
artikel
|
| 33 |
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial
|
van der Heijden, Eefje Hanna Martine
|
|
|
|
5 |
p. e260-e269
|
artikel
|
| 34 |
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
|
Stone, John H
|
|
|
|
5 |
p. e328-e336
|
artikel
|
| 35 |
Making inroads on sex and gender
|
The Lancet Rheumatology,
|
|
|
|
5 |
p. e303
|
artikel
|
| 36 |
Michael Barrett: navigating hostile terrain
|
Morgan, Jules
|
|
|
|
5 |
p. e253
|
artikel
|
| 37 |
Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know
|
Marinkovic, Angelina
|
|
|
|
5 |
p. e362-e373
|
artikel
|
| 38 |
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study
|
McCarter, Kaitlin R
|
|
|
|
5 |
p. e274-e283
|
artikel
|
| 39 |
National differences in vaccine hesitancy: a concern for the external validity of vaccine studies
|
Ammitzbøll, Christian
|
|
|
|
5 |
p. e324
|
artikel
|
| 40 |
No perfect therapy for the imperfect COVID-19 cytokine storm
|
Cron, Randy Q
|
|
|
|
5 |
p. e308-e310
|
artikel
|
| 41 |
Painful palmar calcinosis in juvenile dermatomyositis
|
Guliani, Ankur
|
|
|
|
5 |
p. e308
|
artikel
|
| 42 |
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?
|
Crowe, Lindsay A N
|
|
|
|
5 |
p. e293-e304
|
artikel
|
| 43 |
Patients with gout: an under-recognised group at high risk of COVID-19
|
Dalbeth, Nicola
|
|
|
|
5 |
p. e317-e318
|
artikel
|
| 44 |
Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
|
Sen, Parikshit
|
|
|
|
5 |
p. e247-e250
|
artikel
|
| 45 |
Preventing COVID-19-induced pneumonia with anticytokine therapy
|
Monteleone, Giovanni
|
|
|
|
5 |
p. e255-e256
|
artikel
|
| 46 |
Rationale for CD40 pathway blockade in autoimmune rheumatic disorders
|
Pucino, Valentina
|
|
|
|
5 |
p. e292-e301
|
artikel
|
| 47 |
Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis
|
Denton, Christopher P
|
|
|
|
5 |
p. e321-e323
|
artikel
|
| 48 |
Reconciling immunotherapy and autoimmunity: not for the faint of heart
|
Ye, Carrie
|
|
|
|
5 |
p. e243-e245
|
artikel
|
| 49 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
5 |
p. e327
|
artikel
|
| 50 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
5 |
p. e259
|
artikel
|
| 51 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
5 |
p. e252
|
artikel
|
| 52 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
5 |
p. e318
|
artikel
|
| 53 |
Rewriting the rule book for Sjögren's syndrome? The promise of new approaches to old treatments
|
Rasmussen, Astrid
|
|
|
|
5 |
p. e246-e247
|
artikel
|
| 54 |
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
|
Gianfrancesco, Milena A
|
|
|
|
5 |
p. e250-e253
|
artikel
|
| 55 |
Rheumatologists rapidly adjust patient care during COVID-19 pandemic
|
Kirby, Tony
|
|
|
|
5 |
p. e258
|
artikel
|
| 56 |
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Han, MeiLan K
|
|
|
|
5 |
p. e351-e361
|
artikel
|
| 57 |
Self-management of gout using a mobile app
|
Stamp, Lisa K
|
|
|
|
5 |
p. e304-e305
|
artikel
|
| 58 |
Serious infections in patients with systemic lupus erythematosus: how can we prevent them?
|
Nguyen, Yann
|
|
|
|
5 |
p. e245-e246
|
artikel
|
| 59 |
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation
|
Wilby, Martin John
|
|
|
|
5 |
p. e347-e356
|
artikel
|
| 60 |
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial
|
Pratt, Arthur G
|
|
|
|
5 |
p. e337-e346
|
artikel
|
| 61 |
The changing face of psoriatic arthritis
|
Aydin, Sibel Z
|
|
|
|
5 |
p. e313-e315
|
artikel
|
| 62 |
Tocilizumab in patients with giant cell arteritis: for whom and for how long?
|
Quinn, Kaitlin A
|
|
|
|
5 |
p. e314-e315
|
artikel
|
| 63 |
Tuning up UK clinical trials
|
The Lancet Rheumatology,
|
|
|
|
5 |
p. e239
|
artikel
|
| 64 |
Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community
|
The Lancet Rheumatology,
|
|
|
|
5 |
p. e245
|
artikel
|
Tijdschrift beschrijving